Sarepta Therapeutics (SRPT) Tops Q3 EPS by 21c

Sarepta Therapeutics (NASDAQ: SRPT) reported Q3 EPS of ($1.14), $0.21 better than the analyst estimate of ($1.35). Revenue for the quarter came in at $99 million versus the consensus estimate of $98.34 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• KeyBanc lowers Nike rating to Sector Weight on near-term uncertainty
• Darden Restaurants (DRI) PT Raised to $240 at UBS as Stock Remains a 'Quality Compounder'